BIOMAT Database Logo BIOMAT Database Logo

Structure-Activity Relationships of Pyrazolo[1,5-a]pyrimidin-7(4H)-ones as Antitubercular Agents. 2021

Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.

Pyrazolo[1,5-a]pyrimidin-7(4H)-one was identified through high-throughput whole-cell screening as a potential antituberculosis lead. The core of this scaffold has been identified several times previously and has been associated with various modes of action against Mycobacterium tuberculosis (Mtb). We explored this scaffold through the synthesis of a focused library of analogues and identified key features of the pharmacophore while achieving substantial improvements in antitubercular activity. Our best hits had low cytotoxicity and showed promising activity against Mtb within macrophages. The mechanism of action of these compounds was not related to cell-wall biosynthesis, isoprene biosynthesis, or iron uptake as has been found for other compounds sharing this core structure. Resistance to these compounds was conferred by mutation of a flavin adenine dinucleotide (FAD)-dependent hydroxylase (Rv1751) that promoted compound catabolism by hydroxylation from molecular oxygen. Our results highlight the risks of chemical clustering without establishing mechanistic similarity of chemically related growth inhibitors.

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D057166 High-Throughput Screening Assays Rapid methods of measuring the effects of an agent in a biological or chemical assay. The assay usually involves some form of automation or a way to conduct multiple assays at the same time using sample arrays. High-Throughput Screening,High-Throughput Biological Assays,High-Throughput Chemical Assays,High-Throughput Screening Methods,Assay, High-Throughput Biological,Assay, High-Throughput Chemical,Assay, High-Throughput Screening,Biological Assay, High-Throughput,Chemical Assay, High-Throughput,High Throughput Biological Assays,High Throughput Chemical Assays,High Throughput Screening,High Throughput Screening Assays,High Throughput Screening Methods,High-Throughput Biological Assay,High-Throughput Chemical Assay,High-Throughput Screening Assay,High-Throughput Screening Method,High-Throughput Screenings,Screening Assay, High-Throughput,Screening Method, High-Throughput,Screening, High-Throughput

Related Publications

Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
6-Nitroazolo[1,5-a]pyrimidin-7(4H)-ones as Antidiabetic Agents.
December 2017, Archiv der Pharmazie,
Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
Discovery of 4H-pyrazolo[1,5-a]pyrimidin-7-ones as potent inhibitors of hepatitis C virus polymerase.
September 2009, Bioorganic & medicinal chemistry letters,
Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.
March 2011, European journal of medicinal chemistry,
Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel antiproliferative agents: exploration of core and headpiece structure-activity relationships.
March 2007, Bioorganic & medicinal chemistry letters,
Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
Synthesis and structure-activity relationships of pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists.
January 1987, Journal of medicinal chemistry,
Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
Synthesis and pharmacological evaluation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as potential GABAA-R ligands.
March 2017, Bioorganic & medicinal chemistry,
Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
Activation of KCNQ2/3 potassium channels by novel pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives.
January 2011, Pharmacology,
Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
Synthesis and Structure-Activity Relationships for the Anti-Mycobacterial Activity of 3-Phenyl-N-(Pyridin-2-ylmethyl)Pyrazolo[1,5-a]Pyrimidin-7-Amines.
September 2022, Pharmaceuticals (Basel, Switzerland),
Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 C-terminal domain inhibitors against Ewing sarcoma.
February 2023, Bioorganic chemistry,
Sangmi Oh, and M Daben J Libardo, and Shaik Azeeza, and Gary T Pauly, and Jose Santinni O Roma, and Andaleeb Sajid, and Yoshitaka Tateishi, and Caroline Duncombe, and Michael Goodwin, and Thomas R Ioerger, and Paul G Wyatt, and Peter C Ray, and David W Gray, and Helena I M Boshoff, and Clifton E Barry
Synthesis and anticonvulsant activity of 7-phenyl-6,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-ones and their derivatives.
July 2011, European journal of medicinal chemistry,
Copied contents to your clipboard!